

# Effect of Increased Immunosuppression on Developmental Myoclonus Syndrome (OMS)

Journal of Child Neurology

30, 976-982

DOI: [10.1177/0883073814549581](https://doi.org/10.1177/0883073814549581)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The "neuro" of neuroblastoma: <scp>N</scp>euroblastoma as a neurodevelopmental disorder. <i>Annals of Neurology</i> , 2016, 80, 13-23.	2.8	54
2	Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 465-467.	1.4	1
3	Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 641-648.	1.4	40
4	Autoimmune neurologic disorders in children. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 485-510.	1.0	9
5	Neuroblastoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16078.	18.1	907
6	Sensory Processing Difficulties in Opsoclonus-Myoclonus Syndrome. <i>Journal of Child Neurology</i> , 2016, 31, 965-970.	0.7	5
7	Opsoclonus-Myoclonus Syndrome, Neuroblastoma, and Insulin-Dependent Diabetes Mellitus in a Child: A Unique Patient. <i>Pediatric Neurology</i> , 2016, 55, 68-70.	1.0	5
8	Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome. <i>Brain and Development</i> , 2016, 38, 439-448.	0.6	47
9	Rituximab treatment for relapsed opsoclonus"myoclonus syndrome. <i>Brain and Development</i> , 2016, 38, 346-349.	0.6	12
10	Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders. <i>Developmental Medicine and Child Neurology</i> , 2017, 59, 136-144.	1.1	24
11	Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome. <i>Pediatric Neurology</i> , 2017, 73, 48-56.	1.0	28
12	Opsoclonus-Myoclonus Syndrome: A New Era of Improved Prognosis?. <i>Pediatric Neurology</i> , 2017, 72, 65-69.	1.0	29
13	Cancer and Autoimmunity: Paraneoplastic Neurological Disorders Associated With Neuroblastic Tumors. <i>Seminars in Pediatric Neurology</i> , 2017, 24, 180-188.	1.0	9
14	Immune-Mediated CNS Diseases: a Review. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2017, 5, 134-142.	0.3	2
15	Management of Immune-Mediated Paraneoplastic Neurological Disorders. <i>Neurology International Open</i> , 2017, 01, E264-E274.	0.4	3
16	Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study. <i>Frontiers in Neurology</i> , 2017, 8, 468.	1.1	65
17	Opsoclonus Myoclonus Syndrome. , 2017, , 938-944.		4
18	Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 586-594.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Principles and approaches to the treatment of immune-mediated movement disorders. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 292-300.	0.7	24
20	Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy (RITe-Cl) for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations. <i>Neuropediatrics</i> , 2018, 49, 123-134.	0.3	6
21	Enigmatic entities: opsoclonus myoclonus ataxia syndrome linked to neuroblastoma. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 3-5.	2.7	6
22	Autoimmune Movement Disorders in Children. <i>Seminars in Pediatric Neurology</i> , 2018, 25, 92-112.	1.0	3
23	Autoimmune Encephalitis in Children. <i>Journal of Pediatric Neurology</i> , 2018, 16, 192-201.	0.0	1
24	Therapeutic plasma exchange for a case of refractory opsoclonus myoclonus ataxia syndrome. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26819.	0.8	7
25	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBLOOP3): a randomised, open-label, phase 3 trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 25-34.	2.7	38
27	Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome. <i>Pediatric Neurology</i> , 2018, 85, 71-75.	1.0	12
28	Current behavioral assessments of movement disorders in children. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 863-875.	1.9	8
29	Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (Tumor vs. No tumor) in a cohort of 356 US children. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27097.	0.8	21
30	Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. <i>Journal of Pediatric Neurology</i> , 2018, 16, 202-216.	0.0	1
31	An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27776.	0.8	16
32	Current therapies and therapeutic decision making for childhood-onset movement disorders. <i>Movement Disorders</i> , 2019, 34, 637-656.	2.2	24
33	Update on opsoclonus-myoclonus syndrome in adults. <i>Journal of Neurology</i> , 2019, 266, 1541-1548.	1.8	76
34	Autoimmune and Autoantibody-Associated Encephalomyelopathies. , 2020, , 1067-1114.		1
35	Síndrome opsoclono-mioclono: características clínicas, aspectos terapéuticos y factores pronósticos en una cohorte pediátrica española. <i>Neurología</i> , 2023, 38, 93-105.	0.3	1
36	IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1444-1449.	1.1	10
37	The Treatment of Opsoclonus-Myoclonus Syndrome Secondary to Neuroblastic Tumours: Single-Centre Experience and Literature Review. <i>Medicina (Lithuania)</i> , 2020, 56, 412.	0.8	4

#	ARTICLE	IF	CITATIONS
38	Opsoclonus-myoclonus syndrome: Experience in a tertiary hospital in the last 12 years. <i>Anales De Pediatr�a (English Edition)</i> , 2020, 93, 339-342.	0.1	0
39	Treatment and revaccination of children with paraneoplastic opsoclonusâ€myoclonusâ€ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28319.	0.8	6
41	Paraneoplastic Neurologic Syndromes. , 2020, , 676-687.e5.		1
42	Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 675-686.	1.4	6
43	Rapid Resolution of Enterovirus 71-Associated Opsoclonus Myoclonus Syndrome on Intravenous Immunoglobulin. <i>Child Neurology Open</i> , 2017, 4, 2329048X1773321.	0.5	11
44	Movement Disorders Presenting in Childhood. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 1159-1185.	0.4	10
45	Clinical Analysis of Pediatric Opsoclonus-Myoclonus Syndrome in One of the National Children's Medical Center in China. <i>Frontiers in Neurology</i> , 2021, 12, 744041.	1.1	4
46	Therapeutic decision making in autoimmune and inflammatory disorders of the central nervous system in children. <i>Journal of International Child Neurology Association</i> , 0, , .	0.0	0
47	Opsoclonus-Myoclonus-Ataxia Syndrome in Children: Clinical Characteristics and Treatment Response. <i>Journal of the Korean Child Neurology Society</i> , 2016, 24, 251-256.	0.0	0
49	Modern principles of diagnosis and treatment of Kinsbourne encephalopathy (a clinical case). <i>ZaporoÅ¼skij Medicinskij Å½urnal</i> , 2020, .	0.0	0
50	Opsoclonus-Myoclonus Syndrome in Children and Adolescents: A Therapeutic Challenge. <i>Children</i> , 2021, 8, 965.	0.6	5
51	Movement Disorders in the Structure of the Different Mental Processes Types in Child with Opsoclonus-Myoclonus Syndrome. <i>KliniÅeskaÅ¢ I SpecialânaÅ¢ PsihologiÅ¢</i> , 2020, 9, 229-245.	0.1	2
52	The Efficacy and Safety of Rituximab for the Treatment of Pediatric Autoimmune Neuroinflammatory Disorders at a Single Center. <i>Annals of Child Neurology</i> , 2020, 28, 30-36.	0.0	2
53	Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome. <i>Translational Pediatrics</i> , 2022, 11, 368-374.	0.5	2
54	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	26
55	Monocentric retrospective clinical outcome in a group of 13 patients with opsoclonus myoclonus syndrome, proposal of diagnostic algorithm and review of the literature. <i>European Journal of Paediatric Neurology</i> , 2022, 40, 18-27.	0.7	1
56	Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome. <i>European Journal of Paediatric Neurology</i> , 2022, 41, 19-26.	0.7	4
57	Presence of identical B-cell clone in both cerebrospinal fluid and tumor tissue in a patient with opsoclonusâ€myoclonus syndrome associated with neuroblastoma. <i>Pediatric Hematology and Oncology</i> , 0, , 1-8.	0.3	0

#	ARTICLE	IF	CITATIONS
58	Opsoclonus-myoclonus syndrome: clinical characteristics, therapeutic considerations, and prognostic factors in a Spanish paediatric cohort. <i>Neurología (English Edition)</i> , 2022, , .	0.2	1
59	Child with Ataxia. , 2022, , 487-500.		0
60	“Pediatrician’s Approach to Recognizing Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome” <i>Clinical Pediatrics</i> , 0, , 000992282211474.	0.4	2
61	Five Years Follow-up of Opsoclonus-Myoclonus-Ataxia Syndrome-Associated Neurogenic Tumors in Children. <i>Neuropediatrics</i> , 2024, 55, 057-062.	0.3	0
62	Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments. <i>Journal of Pediatric Hematology/Oncology</i> , 2023, 45, 152-154.	0.3	0
64	Opsoclonus Myoclonus Syndrome: A Child with “Jumping Vision”, 2023, , 203-207.		0
65	Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD): a collaborative review of the current understanding. <i>Clinical Autonomic Research</i> , 2023, 33, 251-268.	1.4	3
67	Paraneoplastic cerebellar and brainstem disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2024, , 173-191.	1.0	0